Glaxo has bird flu ‘breakthrough’
UK drugs firm GlaxoSmithKline believes it has developed a vaccine for the H5N1 deadly strain of bird flu that may be capable of being mass produced by 2007.
Glaxo said its new vaccine would give limited immunity to bird flu in the event of a pandemic. A second shot would be necessary for complete immunisation, the company said.
Glaxo says its vaccine is more akin to shotgun treatment than a “precision-rifle cure”, which means that it appears to be effective against small mutations in the virus strain.
However, it has yet to determine the effectiveness of the vaccine against big changes in the H5N1 strain.
Click here for the complete BBC article
No comments
No comments yet. Be the first.
Leave a reply
Page 1 of 0